SG147472A1 - N-thiazol-2-yl-benzamide derivatives - Google Patents

N-thiazol-2-yl-benzamide derivatives

Info

Publication number
SG147472A1
SG147472A1 SG200807988-1A SG2008079881A SG147472A1 SG 147472 A1 SG147472 A1 SG 147472A1 SG 2008079881 A SG2008079881 A SG 2008079881A SG 147472 A1 SG147472 A1 SG 147472A1
Authority
SG
Singapore
Prior art keywords
thiazol
benzamide derivatives
agonists
receptor
benzamide
Prior art date
Application number
SG200807988-1A
Other languages
English (en)
Inventor
Anette Graven Sams
Mogens Larsen
Gitte Mikkelsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG147472A1 publication Critical patent/SG147472A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG200807988-1A 2003-10-27 2004-10-25 N-thiazol-2-yl-benzamide derivatives SG147472A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301579 2003-10-27
DKPA200400229 2004-02-13

Publications (1)

Publication Number Publication Date
SG147472A1 true SG147472A1 (en) 2008-11-28

Family

ID=34524309

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807988-1A SG147472A1 (en) 2003-10-27 2004-10-25 N-thiazol-2-yl-benzamide derivatives

Country Status (28)

Country Link
US (2) US20060154974A1 (fr)
EP (2) EP1682129B1 (fr)
JP (1) JP2007509083A (fr)
KR (1) KR20060093726A (fr)
AR (1) AR047621A1 (fr)
AT (1) ATE354365T1 (fr)
AU (1) AU2004283019A1 (fr)
BR (1) BRPI0415661A (fr)
CA (1) CA2542816A1 (fr)
CO (1) CO5690582A2 (fr)
CY (1) CY1106526T1 (fr)
DE (1) DE602004004925T2 (fr)
DK (1) DK1682129T3 (fr)
EA (2) EA010790B1 (fr)
ES (1) ES2279414T3 (fr)
HR (1) HRP20070194T3 (fr)
IL (1) IL175189A0 (fr)
IS (1) IS8364A (fr)
ME (1) MEP6708A (fr)
MX (1) MXPA06004436A (fr)
NO (1) NO20062417L (fr)
PL (1) PL1682129T3 (fr)
PT (1) PT1682129E (fr)
RS (1) RS20060289A (fr)
SG (1) SG147472A1 (fr)
SI (1) SI1682129T1 (fr)
TW (1) TW200524887A (fr)
WO (1) WO2005039572A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106040A1 (en) 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
WO2006032273A1 (fr) 2004-09-22 2006-03-30 H. Lundbeck A/S Derives de 2-acylaminothiazole
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
PL1921077T3 (pl) * 2005-08-02 2018-01-31 Kyowa Hakko Kirin Co Ltd Środek do zapobiegania i/lub leczenia zaburzenia snu
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2210891A1 (fr) * 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
RU2483722C1 (ru) * 2012-05-22 2013-06-10 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Аминотиазольные производные усниновой кислоты как новые противотуберкулезные агенты
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE855120C (de) * 1950-10-08 1953-01-05 Schering Ag Verfahren zur Herstellung von Aminosalicylsaeureamiden
JP2903339B2 (ja) * 1990-10-12 1999-06-07 大日精化工業株式会社 電子写真感光体
WO1998017654A1 (fr) * 1996-10-24 1998-04-30 Zeria Pharmaceutical Co., Ltd. Derives de benzoylaminothiazole substitues et medicaments les contenant
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2002059100A1 (fr) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes halogene ayant un agonisme envers le recepteur de thrombopoietine
US7429593B2 (en) * 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
SI3002283T1 (en) * 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives

Also Published As

Publication number Publication date
DE602004004925D1 (de) 2007-04-05
EP1803455A1 (fr) 2007-07-04
RS20060289A (en) 2008-06-05
TW200524887A (en) 2005-08-01
EA010790B1 (ru) 2008-10-30
KR20060093726A (ko) 2006-08-25
JP2007509083A (ja) 2007-04-12
CY1106526T1 (el) 2012-01-25
DE602004004925T2 (de) 2007-10-31
IS8364A (is) 2006-03-20
PT1682129E (pt) 2007-04-30
ES2279414T3 (es) 2007-08-16
US20060154974A1 (en) 2006-07-13
EA200600860A1 (ru) 2006-08-25
US20090247593A1 (en) 2009-10-01
AU2004283019A1 (en) 2005-05-06
BRPI0415661A (pt) 2006-12-19
CA2542816A1 (fr) 2005-05-06
ATE354365T1 (de) 2007-03-15
IL175189A0 (en) 2006-09-05
MXPA06004436A (es) 2006-06-20
PL1682129T3 (pl) 2007-07-31
NO20062417L (no) 2006-05-26
AR047621A1 (es) 2006-02-01
EA200801734A1 (ru) 2008-12-30
EP1682129A1 (fr) 2006-07-26
MEP6708A (xx) 2010-02-10
CO5690582A2 (es) 2006-10-31
HRP20070194T3 (en) 2007-06-30
DK1682129T3 (da) 2007-06-11
WO2005039572A1 (fr) 2005-05-06
EP1682129B1 (fr) 2007-02-21
SI1682129T1 (sl) 2007-06-30

Similar Documents

Publication Publication Date Title
NO20062417L (no) N-tiazol-2-yl-benzamidderivater
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
TW200503710A (en) Novel compounds
EA200500017A1 (ru) Новые соединения
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
GB0325956D0 (en) Novel compounds
RS20050616A (en) Pyrazoles and methods of making and using the same
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
MXPA05010652A (es) Pirazoles sustituidos.
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
WO2003099266A3 (fr) Acetamides et benzamides utilises dans le traitement d'une dysfonction sexuelle
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
TN2009000109A1 (en) New benzamide derivatives as brad ykinin antagonists
GB0513886D0 (en) Novel compounds
MXPA05011962A (es) Oxiarenos substituidos.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
NO20072060L (no) 2-acylaminotiazolderivater
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
MXPA04003544A (es) Benzotriazepinas como ligandos del receptor de gastrina y colecistocinina.